Table 4 Remission rate after 1 year of follow-up treatment between PLA2R+ and PLA2R- group
Total | CR | PR | CR + PR |
|---|---|---|---|
PLA2R- | 13/29 (44.8%) | 13/29 (44.8%) | 26/29 (89.7%) |
FSGS- (N = 27) | 12/27 (44.4%) | 12/27 (44.4%) | 24/27 (88.9%) |
FSGS+ (N = 2) | 1/2 (50.0%) | 1/2 (50.0%) | 2/2 (100%) |
PLA2R+ FSGS- (N = 100) FSGS+(N = 18) | 33/118 (27.9%) 28/100 (28.0%) 5/18 (27.8%) | 56/118 (47.5%) 47/100 (47.0%) 9/18 (50.0%) | 89/118 (75.4%) 75/102 (73.5%) 14/18 (77.8%) |
Low titer PLA2R+(14–86) | |||
FSGS - (N = 47) | 19/47 (40.4%) | 20/47 (42.6%) | 39/47 (82.9%) |
FSGS + (N = 9) | 3/9 (33.3%) | 4/9 (44.4%) | 7/9 (77.8%) |
Low titer PLA2R+(87–204) | |||
FSGS- (N = 21) | 4/21 (19.05%) | 14/21 (66.7%) | 18/21 (85.7%) |
FSGS + (N = 4) | 1/4 (25.0%) | 2/4 (50.0%) | 3/4 (75.0%) |
High titer PLA2R+(> 204) | |||
FSGS - (N = 32) | 6/32 (18.7%) | 12/32 (37.5%) | 18/32 (56.3%) |
FSGS + (N = 5) | 1/5 (20.0%) | 2/5 (40.0%) | 3/5 (60.0%) |